Alkermes plc $ALKS Position Lifted by Commodore Capital LP

Commodore Capital LP boosted its position in shares of Alkermes plc (NASDAQ:ALKS) by 26.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 3,096,754 shares of the company’s stock after acquiring an additional 646,754 shares during the quarter. Alkermes comprises 4.5% of Commodore Capital LP’s holdings, making the stock its 7th biggest position. Commodore Capital LP’s holdings in Alkermes were worth $92,903,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALKS. Assetmark Inc. boosted its holdings in shares of Alkermes by 933.8% in the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 747 shares during the period. Johnson Financial Group Inc. acquired a new position in shares of Alkermes in the 3rd quarter valued at $31,000. Hantz Financial Services Inc. raised its position in Alkermes by 395.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after purchasing an additional 989 shares during the last quarter. Osaic Holdings Inc. raised its position in Alkermes by 56.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after purchasing an additional 701 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in Alkermes by 163.3% during the 3rd quarter. Bessemer Group Inc. now owns 2,222 shares of the company’s stock worth $67,000 after purchasing an additional 1,378 shares during the period. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Price Performance

NASDAQ:ALKS opened at $27.76 on Friday. The firm has a market cap of $4.63 billion, a price-to-earnings ratio of 19.41, a price-to-earnings-growth ratio of 6.92 and a beta of 0.53. The firm’s fifty day moving average price is $31.58 and its 200 day moving average price is $30.19. Alkermes plc has a 1-year low of $25.17 and a 1-year high of $36.32.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The firm had revenue of $384.55 million for the quarter, compared to analysts’ expectations of $380.44 million. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The firm’s quarterly revenue was down 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, analysts expect that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Insider Activity

In other Alkermes news, EVP David Joseph Gaffin sold 2,034 shares of Alkermes stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $29.29, for a total value of $59,575.86. Following the sale, the executive vice president owned 237,660 shares of the company’s stock, valued at approximately $6,961,061.40. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shane Cooke sold 61,200 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the transaction, the director owned 103,744 shares in the company, valued at $3,586,430.08. The trade was a 37.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 157,434 shares of company stock valued at $5,305,794. Company insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on ALKS. HC Wainwright reissued a “neutral” rating and set a $43.00 price objective on shares of Alkermes in a research report on Thursday, February 26th. Bank of America upped their target price on shares of Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, February 20th. Royal Bank Of Canada decreased their target price on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Weiss Ratings reissued a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. Finally, Zacks Research cut Alkermes from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.